U.S. Antibody Drug Conjugates Market Size & Outlook
- Pharmaceuticals
- Oncology Drugs
- Antibody Drug Conjugates Market Outlook
- Oncology Drugs
Global Market
Related Markets
Ask Prism AI anything about the antibody drug conjugates market
Get a cited answer from GVR research in seconds: segment shares, growth drivers, regulation and forecast assumptions.
U.S. antibody drug conjugates market highlights
- The U.S. antibody drug conjugates market generated a revenue of USD 5,168.4 million in 2025 and is expected to reach USD 11,150.0 million by 2033.
- The U.S. market is expected to grow at a CAGR of 9.4% from 2026 to 2033.
- In terms of segment, breast cancer was the largest revenue generating application in 2025.
- Urothelial Carcinoma is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2025 | USD 5,168.4 million |
| Market revenue in 2033 | USD 11,150.0 million |
| Growth rate | 9.4% (CAGR from 2026 to 2033) |
| Largest segment | Breast cancer |
| Fastest growing segment | Urothelial Carcinoma |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Breast Cancer, Blood Cancer, Urothelial Carcinoma, Ovarian Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, U.S. accounted for 35.7% of the global antibody drug conjugates market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2033.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 361.1 million by 2033.
The U.S.is a major market for ADCs, owing to factors such as high awareness by healthcare professionals about ADCs, presence of advanced ADCs, and high R&D investment by manufacturers. For instance, three new ADCs, Polivy, Padcev, and Enhertu, were approved in 2019 in the U.S.
In 2020, an accelerated FDA approval was granted to Blenrep (belantamab mafodotin-blmf), an ADC intended for treating adult patients with multiple myeloma who have previously received at least 4 prior therapies, including an anti-CD-38 monoclonal antibody, a proteasome inhibitor and immunomodulatory agent.
Furthermore, favorable reimbursement policies are expected to drive market growth in the country. For instance, Gene tech provides a co-pay program for Kadcyla to patients, alleviating their out-of-pocket expenses on the condition that the medication is being administered for an FDA-approved indication, while making the assistance ineligible for patients that are using state or federal programs to pay for their medications.
No credit card required*
Publish Date: Nov 10, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Gilead Sciences Inc | View profile | 18,000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | www.gilead.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49,095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | www.takeda.com |
| Daiichi Sankyo Co Ltd | View profile | 17,435 | 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 | www.daiichisankyo.com |
| Astellas Pharma Inc | View profile | 14,484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | www.astellas.com |
| GlaxoSmithKline Consumer Healthcare (GSK CH India) | View profile | 1001-5000 | Gurgaon, Haryana, India, Asia | india-consumer.gsk.com/ |
| ADC Therapeutics SA | View profile | 274 | Route de la Corniche 3B, Biopole, Epalinges, Switzerland, 1066 | www.adctherapeutics.com |
U.S. Antibody Drug Conjugates Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Antibody Drug Conjugates Market Outlook will help companies and investors design strategic landscapes.
Breast Cancer was the largest segment with a revenue share of 46.82% in 2025.
Horizon Databook has segmented the U.S. antibody drug conjugates market based on breast cancer, blood cancer, urothelial carcinoma, ovarian cancer covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S.is a major market for ADCs, owing to factors such as high awareness by healthcare professionals about ADCs, presence of advanced ADCs, and high R&D investment by manufacturers. For instance, three new ADCs, Polivy, Padcev, and Enhertu, were approved in 2019 in the U.S.
In 2020, an accelerated FDA approval was granted to Blenrep (belantamab mafodotin-blmf), an ADC intended for treating adult patients with multiple myeloma who have previously received at least 4 prior therapies, including an anti-CD-38 monoclonal antibody, a proteasome inhibitor and immunomodulatory agent.
Furthermore, favorable reimbursement policies are expected to drive market growth in the country. For instance, Gene tech provides a co-pay program for Kadcyla to patients, alleviating their out-of-pocket expenses on the condition that the medication is being administered for an FDA-approved indication, while making the assistance ineligible for patients that are using state or federal programs to pay for their medications.
- U.S. Antibody Drug Conjugates Market Application Outlook (Revenue, USD Million , 2021-2033)
- Breast Cancer
- Blood Cancer
- Urothelial Carcinoma
- Ovarian Cancer
- Others
- U.S. Antibody Drug Conjugates Market Technology Outlook (Revenue, USD Million , 2021-2033)
- Cleavable Linker
- Non-Cleavable Linker
- Others
- U.S. Antibody Drug Conjugates Market Payload Outlook (Revenue, USD Million , 2021-2033)
- Auristatins (MMAE, MMAF)
- Maytansinoids (DM1, DM4)
- Calicheamicin Derivatives
- Topoisomerase I Inhibitors (SN-38, DXd)
- Pyrrolobenzodiazepine (PBD) Dimers
- Others
- U.S. Antibody Drug Conjugates Market Product Outlook (Revenue, USD Million , 2021-2033)
- Kadcyla (ado-trastuzumab emtansine)
- Enhertu (trastuzumab deruxtecan)
- Trodelvy (sacituzumab govitecan)
- Adcetris (brentuximab vedotin)
- Polivy (polatuzumab vedotin)
- Others (Padcev, Tivdak, Elahere, Zynlonta, Mylotarg, Besponsa)
- U.S. Antibody Drug Conjugates Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacy
- Specialty Pharmacy
- Others
Reasons to subscribe to Antibody Drug Conjugates Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Antibody Drug Conjugates Market Outlook databook
- Our clientele includes a mix of Antibody Drug Conjugates Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Antibody Drug Conjugates Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Antibody Drug Conjugates Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Antibody Drug Conjugates Market, 2021-2033 (US$M)
U.S. antibody drug conjugates market statistics, by application, 2021-2033 (US$M)
